Safety and Immunogenicity of a Combination: Measles, Mumps, Rubella and Varicella Vaccine (ProQuad®)

Kuter, Barbara J.; Brown, Michelle; Hartzel, Jonathan; Williams, Wendy R.; EvesiKaren, A; Black, Steve; Shinefield, Henry R.; Reisinger, Keith S.; Marchant, Colin D.; Sullivan, Bradley J.; Thear, Marci; Klopfer, Stephanie O.; Xu, Jin; Gress, Jacqueline; Schödel, Florian

doi:10.4161/hv.2.5.3246

Cited by 50 publications

(29 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The subjects vaccinated in the present study also had a similar incidence of 'any fever' from days 0 to 42 after dose 1 (IM group, 72.9%; SC group, 70.4%) to subjects of a similar age vaccinated in other studies, where the incidence of 'any fever' ranged from 67.7% to 78.0% [25,33,37]. The present study confirms results from previous studies in which the second dose was given in the second year of life [18,19,38] and supports the shorter vaccination schedules now endorsed by the WHO, which are expected to result in better compliance. High vaccine coverage rates result in increased herd immunity and therefore reduce the potential for outbreaks [33].…”

Section: Discussionsupporting

confidence: 94%

Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles–mumps–rubella–varicella vaccine to children aged 11–21 months

et al. 2010

View full text Add to dashboard Cite

This study compared intramuscular and subcutaneous administration of two doses of measles-mumps-rubella-varicella (MMRV) combination vaccine (Priorix-Tetra, GlaxoSmithKline Biologicals) in children. Healthy children (N = 328) were randomised to receive MMRV either intramuscularly or subcutaneously. Reactogenicity was similar between treatment groups for immediate vaccination pain, vaccination site pain, redness and incidence of fever and rashes. Slightly less vaccination site swelling occurred during days 0-3 of the post-vaccination period after intramuscular administration. Seroconversion rates for all components, 42-56 days post-dose 2, ranged from 99.3% to 100% in the intramuscular group and from 98.6% to 100% in the subcutaneous. Cell-mediated immunity data supported the humoral immunogenicity findings. In summary, the MMRV vaccine is well tolerated and highly immunogenic when administered either subcutaneously or intramuscularly to children in the second year of life.

show abstract

Section: Discussionsupporting

confidence: 94%

Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles–mumps–rubella–varicella vaccine to children aged 11–21 months

et al. 2010

View full text Add to dashboard Cite

show abstract

“…These questions are particularly relevant for vaccines, such as measles-containing vaccines, that have known associations with postvaccination febrile seizures. 9,[16][17][18][19][20][21] …”

Section: Discussionmentioning

confidence: 99%

Timely Versus Delayed Early Childhood Vaccination and Seizures

et al. 2014

View full text Add to dashboard Cite

WHAT'S KNOWN ON THIS SUBJECT: Reasons for childhood immunization delay include parental intent and barriers such as transportation. To date there has been 1 study of the association of delayed vaccination and seizures, which found measlesmumps-rubella and measles-mumps-rubella-varicella vaccines are both associated with a higher rate of seizures if received after 15 months of age.WHAT THIS STUDY ADDS: Our study found no association between the timing of vaccination and occurrence of seizures in the first year of life. By using different methods, our results support the observation that delaying vaccination with measles-containing vaccines past 15 months of age increases the incidence of postvaccination seizures. abstract BACKGROUND: Little is known regarding the timing of childhood vaccination and postvaccination seizures.

show abstract

“…Combined vaccine products containing the VZV Oka strain have been developed as well. For instance, GSK Biologicals and Merck & Co., Inc., developed combined tetravalent measlesmumps-rubella-varicella vaccines (Priorix-Tetra and ProQuad, respectively), providing the benefits of measles-mumps-rubella and varicella vaccination in a single injection (19,30,35,48,71,72,79).…”

mentioning

confidence: 99%